Post by icemandios on May 1, 2018 13:33:41 GMT
ChromaDex Remains Confident Amidst Inter Partes Review (IPR) Procedural Changes
SAS Supreme Court decision regarding challenged claims in an IPR has no effect on U.S. Patent 8,197,807
IRVINE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the Patent Trial and Appeal Board (PTAB) has published a Guidance as to how it will apply last week’s Supreme Court of the United States decision (SAS Institute Inc. v Iancu) to trials in pending IPRs.
The PTAB will now institute trial on all challenged claims in an IPR as long as Petitioner has met its initial “reasonable likelihood of success” burden as to least one of those claims. This has no effect on the PTAB’s decision not to institute trial on any of the claims of U.S. Patent 8,197,807.
The PTAB’s implementation of the Supreme Court’s mandate does affect claim 2 of U.S. Patent No. 8,383,086 ("the '086 patent") despite the fact that the PTAB previously determined that Elysium had not met its ”reasonable likelihood of success” burden in the context of that claim, trial in the IPR will now address it together with the claims on which Elysium did meet its initial burden. This is procedural, not substantive. The PTAB has not changed its previous decision that Elysium had failed to meet its initial burden as to Claim 2. ChromaDex remains confident that it will prevail after trial in the IPR as to all claims of the '086 patent, including claim 2.
ChromaDex holds a robust global patent portfolio of 20 patents covering the production and distribution of NIAGEN® nicotinamide riboside.
About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
SAS Supreme Court decision regarding challenged claims in an IPR has no effect on U.S. Patent 8,197,807
IRVINE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the Patent Trial and Appeal Board (PTAB) has published a Guidance as to how it will apply last week’s Supreme Court of the United States decision (SAS Institute Inc. v Iancu) to trials in pending IPRs.
The PTAB will now institute trial on all challenged claims in an IPR as long as Petitioner has met its initial “reasonable likelihood of success” burden as to least one of those claims. This has no effect on the PTAB’s decision not to institute trial on any of the claims of U.S. Patent 8,197,807.
The PTAB’s implementation of the Supreme Court’s mandate does affect claim 2 of U.S. Patent No. 8,383,086 ("the '086 patent") despite the fact that the PTAB previously determined that Elysium had not met its ”reasonable likelihood of success” burden in the context of that claim, trial in the IPR will now address it together with the claims on which Elysium did meet its initial burden. This is procedural, not substantive. The PTAB has not changed its previous decision that Elysium had failed to meet its initial burden as to Claim 2. ChromaDex remains confident that it will prevail after trial in the IPR as to all claims of the '086 patent, including claim 2.
ChromaDex holds a robust global patent portfolio of 20 patents covering the production and distribution of NIAGEN® nicotinamide riboside.
About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.